SPRO Stock News & Analysis | Latest Updates

Spero Therapeutics Announces Second Quarter 2025 Operating Results and Provides a Business Update

CAMBRIDGE, Mass., Aug. 12, 2025 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a clinical-stage biopharmaceutical company focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (MDR) bacterial infections, today announced financial results for the second quarter ended June 30, 2025, and provided a business update.

August 12, 2025Earnings

SPRO News

Spero Therapeutics Announces Second Quarter 2025 Operating Results and Provides a Business Update

Spero Therapeutics Shares Halted On Circuit Breaker To The Upside, Stock Now Up 228.4%

Spero Therapeutics Q1 EPS $(0.25) Beats $(0.55) Estimate, Sales $5.87M Miss $11.00M Estimate

An Overview of Spero Therapeutics's Earnings

Spero Therapeutics Appoints Esther Rajavelu As President And Chief Executive Officer, Effective May 2

Spero Therapeutics Q4 EPS $(0.38) Misses $(0.31) Estimate, Sales $15.04M Beat $6.20M Estimate

A Glimpse of Spero Therapeutics's Earnings Potential

Spero Therapeutics Has Appointed Esther Rajavelu As Interim President And CEO, Stepping In For Sath Shukla, Who Has Agreed To A Voluntary Paid Administrative Leave For An Interim Period, The Board Has Also Appointed Director Frank Thomas As Chairman Of Th

What 4 Analyst Ratings Have To Say About Spero Therapeutics

Evercore ISI Group Downgrades Spero Therapeutics to In-Line, Maintains Price Target to $5

TD Cowen Downgrades Spero Therapeutics to Hold

Cantor Fitzgerald Reiterates Overweight on Spero Therapeutics

Spero Therapeutics Q3 2024 GAAP EPS $(0.32) Beats $(0.36) Estimate, Sales $13.469M Beat $7.667M Estimate

HC Wainwright & Co. Maintains Buy on Spero Therapeutics, Lowers Price Target to $5

HC Wainwright & Co. Reiterates Buy on Spero Therapeutics, Maintains $7 Price Target

Cowen & Co. Downgrades Spero Therapeutics to Market Perform

Evercore ISI Group Downgrades Spero Therapeutics to In-Line, Lowers Price Target to $2

Spero Therapeutics Shares Resume Trading, Down 61%

FDA Identifies Review Issues For Spero's Tebipenem Application, Shares Plunge

Spero Therapeutics Shares Halted On Circuit Breaker, Down 61%

Spero Therapeutics Shares Resume Trading, Down 57%

Spero Therapeutics Shares Halted On Circuit Breaker To Upside; Down 54%

Spero Therapeutics Shares Resume Trade

Spero Therapeutics Shares Haled On Circuit Breaker

Spero Therapeutics Shares Down ~41% Premarket Following Strategic Direction News

UPDATE: Spero Restructuring Related To Cessation Of Commercialization Activities For Tebipenem Will Reduce Co.'s Workforce From 146 Full-Time Employees To ~35 Employees; Co. Will Incur $8M In Costs Related To Workforce Reduction

Spero Therapeutics Recently Reported Will Immediately Defer Current Commercialization Activities For Tebipenem Based On Feedback From Recent Late Cycle Meeting With FDA Related To Co.'s New Drug Application